This study focuses on advanced MTAP-null solid tumors, which are cancers characterized by the absence of a specific gene called MTAP. The research evaluates a new medication called AMG 193, which will be tested both alone and in combination with another cancer drug called docetaxel. AMG 193 is taken as an oral tablet and belongs to a class of drugs known as PRMT5 inhibitors, which work by blocking certain proteins involved in cancer growth.

The purpose of this research is to understand how safe and effective AMG 193 is when used to treat patients with advanced solid tumors that lack the MTAP gene. The study is divided into multiple parts, with initial phases focusing on finding the right dose and checking how the body processes the medication, while later phases examine how well the treatment works in fighting the cancer.

During the study, participants will receive either AMG 193 alone or in combination with docetaxel. The treatment involves taking tablets by mouth. Throughout the study, doctors will monitor various aspects of the participants’ health and how their cancer responds to the treatment. They will track important measures such as tumor size changes and how long patients live without their disease getting worse.